<DOC>
	<DOCNO>NCT00006098</DOCNO>
	<brief_summary>RATIONALE : PS-341 may stop growth tumor cell block enzymes necessary tumor cell growth . PURPOSE : Phase I trial study effectiveness PS-341 treating patient hematologic cancer .</brief_summary>
	<brief_title>PS-341 Treating Patients With Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose dose-limiting toxicity PS-341 patient hematologic malignancy . II . Determine pharmacodynamics drug patient . III . Determine response drug patient . IV . Determine correlation response malignancies proteasome inhibition apoptosis peripheral blood mononuclear cell ( PBMC ) patient . V. Determine correlation therapy toxicity proteasome inhibition apoptosis PBMC patient . VI . Determine effect drug molecular marker ( i.e. , BCL-2 follicular lymphoma patient t9 ; 22/BCR/ABL chronic lymphocytic leukemia patient ) . VII . Determine correlation interleukin-6 serum level multiple myeloma patient drug dosing , toxicity therapy , extent protease inhibition , response therapy , apoptosis PBMC patient . OUTLINE : This dose-escalation , multicenter study . Patients receive PS-341 IV 30 minute day 1 , 4 , 8 , 11 , 15 , 18 , 22 , 25 follow 2-week rest . Treatment repeat every 6 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos PS-341 maximum tolerate dose ( MTD ) determine . The MTD define dose 2 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : A total 3-30 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm hematologic malignancy include : Acute myeloid leukemia Chronic myelogenous leukemia Acute lymphoblastic leukemia Chronic lymphocytic leukemia Hodgkin 's disease NonHodgkin 's lymphoma Multiple myeloma Myelodysplastic syndrome subtypes : Refractory anemia excess blast ( RAEB ) RAEB transformation Refractory standard treatment curative therapy available Measurable disease Not eligible high priority study PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 6 week Hematopoietic : WBC least 3,000/mm3 Absolute neutrophil count least 1,000/mm3 Platelet count least 50,000/mm3 Hematocrit least 25 % Hepatic : SGOT SGPT less 2.5 time upper limit normal ( ULN ) Bilirubin le 1.5 time ULN Renal : Creatinine clearance great 50 mL/min Cardiovascular : No acute ischemia new conduction system abnormality EKG No prior myocardial infarction within past 6 month No New York Heart Association class III IV congestive heart failure Other : Febrile episodes 38.5 degree C due tumor fever allow No concurrent active infection No grade 1 great National Cancer Institute common toxicity criterion No serious medical psychiatric condition would preclude study Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior immunotherapy No concurrent immunotherapy Chemotherapy : At least 4 week since prior chemotherapy No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy No concurrent radiotherapy Surgery : At least 2 week since prior major surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>